PMID- 32506853
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 2589-451X (Electronic)
IS  - 0255-2922 (Linking)
VI  - 40
IP  - 3
DP  - 2020 Jun
TI  - "Wang-Bi tablet, a patented Chinese medicine, maintains the balance of Th1/Th2 in 
      mice with collagen-induced arthritis".
PG  - 401-406
LID - 10.19852/j.cnki.jtcm.2020.03.006 [doi]
AB  - OBJECTIVE: To investigate the pharmacological mechanism of Wang-Bi tablets 
      (WBTs), a Chinese patented medicine, in rheumatoid arthritis (RA) using mice with 
      collagen-induced arthritis (CIA). METHODS: A mouse model of CIA was induced using 
      bovine type Ⅱ collagen. WBT treatment was administered and efficacy was 
      evaluated. The levels of interferon-gamma (IFN-gamma), interleukin-2 (IL-2), and 
      interleukin-4 (IL-4) were examined using an enzyme-linked immunosorbent assay, 
      and the proportions of Th1 and Th2 were detected using flow cytometry. T-bet and 
      GATA-binding protein 3 (GATA3) expression were demonstrated using Western blot 
      analysis. RESULTS: Paw swelling and the arthritis index decreased significantly 
      following WBT treatment. Histopathological analysis revealed markedly alleviated 
      damage to synovium tissue in the WBT and methotrexate treatment groups. WBT 
      regulated the production of IFN-gamma, IL-2, and IL-4 and modulated Th1 and Th2 cell 
      populations, which might have been induced by the attenuation of Th1 and Th2 cell 
      differentiation through a decrease in the expression of T-bet and an increase in 
      the expression of GATA3 in the synovial tissue in CIA mice. CONCLUSION: These 
      results indicate that WBT may produce a therapeutic effect on CIA through 
      maintaining the balance of Th1/Th2 cells, which could result in a decrease in the 
      autoinflammatory disorder observed in RA.
FAU - Wang, Jianming
AU  - Wang J
AD  - Department of Rheumatology of Traditional Chinese Medicine, China-Japan 
      Friendship Hospital, Beijing 100029, China.
FAU - Luo, Jing
AU  - Luo J
AD  - Department of Rheumatology of Traditional Chinese Medicine, China-Japan 
      Friendship Hospital, Beijing 100029, China.
FAU - Xu, Yuan
AU  - Xu Y
AD  - Department of Rheumatology of Traditional Chinese Medicine, China-Japan 
      Friendship Hospital, Beijing 100029, China.
FAU - Yan, Zeran
AU  - Yan Z
AD  - Department of Rheumatology of Traditional Chinese Medicine, China-Japan 
      Friendship Hospital, Beijing 100029, China.
FAU - Qu, Xiangke
AU  - Qu X
AD  - Integrative Chinese and Western Medicine of excellence in Beijing University of 
      Chinese medicine, Beijing 100029, China.
FAU - Chen, Mengxue
AU  - Chen M
FAU - Tao, Qingwen
AU  - Tao Q
AD  - Department of Rheumatology of Traditional Chinese Medicine, China-Japan 
      Friendship Hospital, Beijing 100029, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - J Tradit Chin Med
JT  - Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan
JID - 8211546
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (GATA3 Transcription Factor)
RN  - 0 (Gata3 protein, mouse)
RN  - 0 (Interleukin-2)
RN  - 207137-56-2 (Interleukin-4)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Animals
MH  - Arthritis, Rheumatoid/*drug therapy/immunology
MH  - Disease Models, Animal
MH  - Drugs, Chinese Herbal/*administration & dosage
MH  - GATA3 Transcription Factor/genetics/immunology
MH  - Humans
MH  - Interferon-gamma/genetics/immunology
MH  - Interleukin-2/genetics/immunology
MH  - Interleukin-4/genetics/immunology
MH  - Male
MH  - Mice
MH  - Mice, Inbred DBA
MH  - Th1 Cells/drug effects/*immunology
MH  - Th2 Cells/drug effects/*immunology
OTO - NOTNLM
OT  - Arthritis, rheumatoid
OT  - Collagen
OT  - Th1-Th2balance
OT  - Wang-Bi tablet
EDAT- 2020/06/09 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/06/08 06:00
PHST- 2020/06/08 06:00 [entrez]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
AID - 3031 [pii]
AID - 10.19852/j.cnki.jtcm.2020.03.006 [doi]
PST - ppublish
SO  - J Tradit Chin Med. 2020 Jun;40(3):401-406. doi: 10.19852/j.cnki.jtcm.2020.03.006.